Back to Trials
NCT07001332NARecruiting

ELEVATE High-Risk PCI Pivotal Study

Magenta Medical Ltd.

Start Date

7/25/2025

Completion Date

9/16/2027

Summary

The ELEVATE III Pivotal Study is a prospective, multi-center, open-label, interventional, randomized, controlled study with an active control group. The study is intended to assess the safety and efficacy of the Elevate™ percutaneous Left Ventricular Assist Device System in patients referred to high-risk percutaneous coronary interventions (HR-PCI).

Detailed Description

The Elevate™ percutaneous Left Ventricular Assist Device System is a temporary (≤ 6 hours) ventricular support device indicated for use during high-risk percutaneous coronary interventions (HR-PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease. Use of the Elevate™ System in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions.

Eligibility Criteria

Age Range: 18 years to 88 years

Inclusion Criteria: 1. Non-emergent, percutaneous coronary intervention is planned on at least one stenotic lesion of a native coronary artery or bypass graft (de novo or restenosis). 2. A heart team that includes an interventional cardiologist and cardiac surgeon has determined that HR- PCI is an appropriate therapeutic option. 3. Participant signed the informed consent. Exclusion Criteria: 1. Cardiogenic shock or acutely decompensated pre-existing chronic heart failure. 2. Prior stroke with any permanent, significant (mRS\>2) neurological deficit, or stroke or TIA within 3 months prior to enrollment. 3. Any condition or scheduled surgery that will require discontinuation of the antiplatelet and/or anticoagulation therapy within 90 days of the index procedure. 4. Evidence of left ventricular thrombus. 5. Aortic valve stenosis/calcification (valve area ≤ 1.5 cm2). 6. ≥ Moderate aortic valve regurgitation (≥ 2+ on a 4-grade scale by transthoracic echocardiography). 7. Femoral access site incompatibility that precludes placement of either the Treatment or Control device. 8. Patient on dialysis. 9. Known or suspected coagulopathy OR abnormal coagulation parameters. 10. Known allergy, sensitivity or intolerance to nickel. 11. Infection of the proposed procedural access site; OR suspected systemic active infection, including any fever or known active COVID-19 infection. 12. Allergy, sensitivity or intolerance to heparin, or contrast media, including known heparin-induced thrombocytopenia (HIT). 13. Any non-cardiac condition with a life expectancy \< 12 months. 14. Subject participation in another investigational drug or device trial (with the exception of post-market registries and observational studies, subject to Sponsor review and approval). 15. Pregnancy or breast-feeding. 16. Subject has other medical, social, or psychological problems that, in the opinion of the Investigator, compromise the participant's ability to provide written informed consent and/or to comply with study procedures. 17. Subject belongs to a vulnerable population.

Interventions

DEVICE

Elevate

DEVICE

Impella

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

High-Risk Percutaneous Coronary Intervention (High-risk PCI)

Locations

Banner-University Medical Center

Phoenix, Arizona 85006

United States

HonorHealth Scottsdale Shea Medical Center/HonorHealth Deer Valley Medical Center

Scottsdale, Arizona 85260

United States

UC San Diego Medical Center

La Jolla, California 92093

United States

University of California at San Francisco Medical Center/Zuckerberg San Francisco General

San Francisco, California 94143

United States

Tampa General/USF

Tampa, Florida 33606

United States

Emory University Hospital / Emory University Hospital Midtown/ Emory Saint Joseph's Hospital

Atlanta, Georgia 30322

United States

Wellstar Health System

Marietta, Georgia 30062

United States

University of Illinois at Chicago

Chicago, Illinois 60612

United States

University of Chicago Medical Center

Chicago, Illinois 60637

United States

St. Elizabeth Healthcare

Edgewood, Kentucky 41017

United States

Massachusetts General Hospital

Boston, Massachusetts 02114

United States

Brigham & Women's Hospital

Boston, Massachusetts 02115

United States

Boston Medical Center

Boston, Massachusetts 02118

United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts 02215

United States

UMass Memorial Medical Center

Worcester, Massachusetts 01605

United States

Henry Ford Health

Detroit, Michigan 48202

United States

Minneapolis Heart Institute

Minneapolis, Minnesota 55407

United States

St. Luke's Hospital of Kansas City

Kansas City, Missouri 64111

United States

Atlantic Health System

Morristown, New Jersey 07960

United States

Robert Wood Johnson University Hospital

New Brunswick, New Jersey 08901

United States

Maimonides Health

Brooklyn, New York 11219

United States

Buffalo General Medical Center

Buffalo, New York 14203

United States

Northwell Health

Manhasset, New York 11030

United States

NYU Langone/Bellevue/Long Island

New York, New York 10023

United States

Mount Sinai

New York, New York 10029

United States

Columbia University Medical Center/NYPH

New York, New York 10032

United States

Weill Cornell Medical Center

New York, New York 10065

United States

Mercy Health

Cincinnati, Ohio 45211

United States

Kaiser Permanente

Clackamas, Oregon 97015

United States

TriStar Centennial Medical Center

Nashville, Tennessee 37203

United States

Inova Schar Heart & Vascular

Falls Church, Virginia 22042

United States

Swedish Cherry Hill

Seattle, Washington 98122

United States

Advocate Aurora Health Research Institute- St. Luke's Medical Center

Milwaukee, Wisconsin 53215

United States